SINTX Technologies
Manufactures silicon-nitride surgical implants and technical ceramic components.
Something off on this page? Send us feedback.
Profile
Manufactures silicon-nitride surgical implants and ceramic components through direct-device sales, OEM supply, contract manufacturing, and grants. Controls processing from powder to finished component at its Salt Lake City facility.
Manufactures medical-grade silicon-nitride implants and components, led by the FDA-cleared SINAPTIC Foot & Ankle Osteotomy Wedge System and the SiNERGY silicon-nitride/PEEK platform. Revenue comes from direct-device sales, spinal OEM supply to CTL Medical, advanced-ceramics contract manufacturing, and grants and contracts. Sales are primarily U.S.-based, while spinal implants made with its material have historical use across Europe, South America, and Asia.
Controls processing from powder through finished component at its Salt Lake City facility, supporting medical-device and technical-ceramics work. Commercializing the cleared device depends on distributor and surgeon adoption, hospital purchasing, reimbursement, and regulatory compliance; active production is concentrated in that certified facility.
Company facts
Key statistics
Year to date −60.3% · Average volume (30d) 170.9K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 11, 2026Q2 FY26 | −$0.73 | −$0.75 | −2.7% | $460.0K | $452.0K | −1.7% | −11.30% |
| May 15, 2026Q1 FY26 | −$0.66 | −$0.70 | −6.1% | $350.0K | $380.0K | +8.6% | −1.76% |
| Mar 18, 2026Q4 FY25 | −$0.55 | −$1.45 | −162.7% | $300.0K | $300.0K | 0.0% | −3.01% |
| Nov 12, 2025Q3 FY25 | −$0.55 | −$3.46 | −529.1% | $200.0K | $208.0K | +4.0% | −10.79% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $369.0K | $100.0K | $208.0K | $341.0K | $380.0K | $452.0K | |
| Gross profit | $123.0K | $6.0K | $93.0K | −$423.0K | −$12.0K | $278.0K | |
| Operating income | −$2.4M | −$2.7M | −$3.4M | −$2.3M | −$3.2M | −$2.9M | |
| Net income | −$2.3M | −$2.3M | −$10.3M | −$2.2M | −$2.8M | −$2.7M | |
| Diluted EPS | −$1.29 | −$0.91 | −$3.46 | −$0.50 | −$0.70 | −$0.75 | |
| Gross margin | 33.3% | 6.0% | 44.7% | -124.0% | -3.2% | 61.5% | |
| Operating margin | -645.8% | -2,665.0% | -1,613.0% | -679.8% | -843.9% | -638.9% |
Fiscal years (4-quarter sums)FY21 $606.0K · FY22 $1.1M · FY23 $1.8M · FY24 $1.6M · FY25 $1.0M
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $3.6M · Total debt $3.0M · Total assets $10.4M · Shareholders' equity $4.8M
Dividends
No dividends on record.
Ownership
Shares outstanding 6.36M · Float 5.35M · 84.1% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Bleichroeder LP | 647.5K | 9.99% | 13G | Aug 13, 2026 |
| Lytton Laurence W | 632.6K | 9.99% | 13G | Jun 9, 2026 |
| Stonepine Capital Management, LLC | 619.6K | 9.90% | 13G | Jun 9, 2026 |
| Sinaptic Holdings, LLC | 281.5K | 7.20% | 13G | Nov 14, 2025 |
| Medtech Ceramics, LP | 250.1K | 9.90% | 13G | Mar 25, 2025 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Feb 25, 2026 | Christopher Michael Lyons | director | +758 | $2.96 |
| Mar 2, 2026 | Christopher Michael Lyons | director | +7,534 | $2.90 |
| Feb 23, 2026 | Jay M. Moyes | director | +1,000 | $2.91 |
| Feb 18, 2026 | Mark Lewis Anderson | director | +3,000 | $3.02 |
| Dec 8, 2025 | Gregg R. Honigblum | director, officer: Chief Investment Officer | +8,200 | $4.26 |
Peers
- Medtronic
Scale spine rival in interbody implants and fusion workflows.
- Stryker
Direct foot-and-ankle device rival with a broad surgical portfolio.
- Zimmer Biomet
Paragon 28 makes it a large foot-and-ankle device rival.
- Johnson & Johnson
DePuy Synthes brings scale to spine and orthopaedic implants.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| SINTX Technologies | $1.48 | −1.33% | $9.5M | — | — | 6.9 | +352.0% |
| Medtronic | $91.58 | +0.42% | $116.78B | 24.5 | 15.3 | 3.2 | +9.9% |
| Stryker | $334.18 | +1.06% | $126.77B | 34.3 | 20.6 | 4.9 | +9.4% |
| Zimmer Biomet | $100.91 | −0.00% | $19.52B | 24.6 | 11.5 | 2.3 | +4.8% |
| Johnson & Johnson | $268.40 | +0.13% | $645.95B | 31.1 | 22.4 | 6.6 | +6.6% |
| Median | 27.8 | 17.9 | 4.1 | +8.0% |